The top amount of exits for fund were in 2013. The fund is constantly included in less than 2 investment rounds annually. The top activity for fund was in 2012. Deals in the range of 5 - 10 millions dollars are the general things for fund.
Besides, a startup requires to be at the age of 6-10 years to receive the investment from the fund. We can highlight the next thriving fund investment areas, such as Biotechnology, Health Care. Among the most popular portfolio startups of the fund, we may highlight Oligomerix, Enanta Pharmaceuticals.
The typical case for the fund is to invest in rounds with 5-6 participants. Despite the Wheatley MedTech Partners, startups are often financed by Techno Venture Management, Oxford Bioscience Partners, Advent International. The meaningful sponsors for the fund in investment in the same round are Yasuda Enterprise Development, Wheatley Partners, Techno Venture Management. In the next rounds fund is usually obtained by Thuja Capital, Techno Venture Management, Oxford Bioscience Partners.
Related Funds
| Fund Name | Location |
| Aleph Capital Partners | England, London, United Kingdom |
| Bharti Enterprises | Delhi, India, New Delhi |
| GMO | Boston, Massachusetts, United States |
| Haflo | Stockholm, Stockholm County, Sweden |
| iHealthtech ,NUS | - |
| Medwell Capital | Alberta, Canada, Edmonton |
| Perivoli Innovations | - |
| Qicheng Information Technology | - |
| Rona Syndicates | California, San Mateo, United States |
| Zhe Xin Ziben | China, Guangdong, Shenzhen |
Notable deals
| Company | Industry | Round Size | Date | Investors | Location |
Oligomerix | $2M | 23 Apr 2012 | New York, United States |
1. You post comments at your own choice and risk. You bear the whole responsibility,related to their substance, content and the fact of publication. We shall not bear anyliability in respect of such comments.
2. While commenting, you shall use only actual, truthful and confirmed data. In thesame time you shall not use vulgar, abusive or defamatory language as well as expresshatred or call to violence or cruelty.
3. We do not intend to delete any comments on the website unless within our “noticeand take down” procedure.
4. We can moderate comments at any time.
5. While commenting, you are under the rule of our website’s terms of use and privacypolicy.
6. We retain our right to delete any comment or any other content of the website at ourwill in case we know or suppose such content is illegal or breaches any lawful right.
Review
- No reviews are submitted yet.
Sign up and get access to full fund profile and advanced analysis.
Full teamIndustries heatmapStages heatmapGeorgaphy breakdownCoinvestorsPortfolio analysisPerformance indexesLatest highlights
Unlock all data Latest deals
| Company | Industry | Round Size | Date | Investors | Location |
Oligomerix | $2M | 23 Apr 2012 | New York, United States |
